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Abstract
Vitamin D (vitD) deficiency is associated with a wide range of 
chronic diseases and conditions, including obesity, and with 
an increasing severity of metabolic dysregulation, such as 
insulin resistance, hyperlipidemia, liver disease, and hyper-
tension, both in children and adults. However, the nature of 
the association between low vitD status and obesity remains 
unclear. This fact has motivated the scientific community to 
conduct genetic association analyses between 25-hy-
droxyvitamin D (25[OH]D)-related genes and obesity traits. 
In this line, the variation in the vitD receptor (VDR) gene rep-
resents the bulk of the findings. Specifically, polymorphisms 
in the VDR gene have been associated with obesity traits in 
some but not all, studies. Thus, results regarding this matter 
remain inconclusive. Other genes aside from VDR have also 
been investigated in relation to obesity-related traits. How-
ever, again, findings have been inconsistent. In general, re-
sults point to the fact that the DBP/GC gene could be an im-
portant protein-linking obesity and vitD status. On the other 
hand, several studies have attempted to determine the mo-
lecular mechanism of the relationship between 25(OH)-D 
levels and obesity. Some of these studies suggest that vitD, 
due to its fat-soluble characteristic, is retained by the adi-
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pose tissue and has the capacity to metabolize 25(OH)-D lo-
cally, and this can be altered during obesity. Additionally, 
vitD is capable of regulating the gene expression related to 
adipogenesis process, inflammation, oxidative stress, and 
metabolism in mature adipocytes. Therefore, the aim of the 
present review was to evaluate the association between 
obesity and vitD deficiency describing the main molecular 
mechanism of the relationship and the link with genetic fac-
tors. Key Messages: Low serum 25(OH)-D is positively associ-
ated with obesity or BMI in adults and children. Circulating 
vitD concentrations are, at least, partially determined by ge-
netic factors. VitD plays an important role in the adipogen-
esis process and inflammation status in adipocytes and adi-
pose tissue. © 2018 S. Karger AG, Basel
Introduction
An adequate vitamin D (vitD) concentration is essen-
tial for growth, development, and health. It plays a rele-
vant role in the regulation of calcium levels and bone me-
tabolism. In addition, recent studies indicate that hypo-
vitaminosis D compromises long-term condition as a 
consequence of its non-calciotropic effects, such as the 
implication/regulation of the immune system, endocrine 
pancreas, liver, skeletal muscle, and adipocytes. In fact, 
vitD deficiency is associated with a wide range of chronic 
diseases and conditions, including obesity, and several 
types of cancers. Suboptimal vitD status has also been as-
sociated with increasing severity of metabolic dysregula-
tion (insulin resistance, hyperlipidemia, liver disease, and 
hypertension) in children and adults [1].
Obesity is defined as an excess amount of body fat and 
constitutes a worldwide epidemiological problem. Cur-
rently, it is the fifth greatest risk factor for mortality [2]. 
The identification of associated factors and risk groups 
related to hypovitaminosis D is critical. Yet, the nature of 
the association between low vitD status and obesity re-
mains unclear. Therefore, the aim of the present review 
was to evaluate the association between obesity and vitD 
deficiency describing the main molecular mechanism of 
the relationship and the link with genetic factors.
VitD Status and Obesity
An association between low vitD and obesity has con-
sistently been shown by cross-sectional studies. VitD sta-
tus is measured by means of the plasma levels of 25-hy-
droxyvitamin D (25[OH]-D) [3]. The Institute of Medi-
cine proposed that serum 25(OH)-D concentrations 
below 50 nmol·L–1 or equal to 20 ng·mL–1 should be con-
sidered to represent a deficiency status of this nutrient [4]. 
The first meta-analysis quantifying the association be-
tween Body mass index (BMI) and vitD deficiency was 
published in 2015 revealing a positive association between 
both of them among the 23 articles included [3]. Indepen-
dent of the age group, the prevalence of vitD deficiency 
was 35% higher in obese subjects compared to the eutro-
phic group and 24% higher than in the overweight group. 
Taking into account the age, up to 37% of obese children 
and adolescents were vitD deficient, while in obese adults 
and elderly individuals, this prevalence was 33%. The re-
sults of this meta-analysis emphasized the prevalence of 
vitD deficiency in obese and overweight individuals.
At the end of 2015, another meta-analysis from differ-
ent populations was published considering 15 studies, 
which included 3,867 subjects with obesity and 9,342 
healthy subjects [5]. As in the first meta-analysis, the re-
sults showed that the prevalence of vitD deficiency was 
different between the obesity and the control groups, and 
the pooled OR (95% CI) was 3.43 (2.33–5.06). The preva-
lence of vitD deficiency was associated with obesity in 
Asians and European-Americans; OR (95% CI) were 3.70 
(1.98–6.90) and 3.09 (1.89–5.04) among Asians and Eu-
ropean-Americans respectively. Nevertheless, the impact 
of several confounding factors, such as diet intake, phys-
ical activity, educational level, season of the year, and 
presence of secondary hyperparathyroidism, were not in-
cluded in any of the meta-analyses due to methodological 
divergences in the studies analyzed and the absence of 
information on these factors.
The worldwide rise in the obesity rate alongside the 
progressive increase of vitD deficiency in children and 
adolescents is alarming. Although literature on children 
and adolescents is scarce compared to that on adults, 
studies show that obese children and adolescents also 
have significantly low serum 25(OH)-D concentrations, 
like their adult counterparts. A large study, reported by 
Turer et al. [6] with a representative sample of American 
6–8-year-old children and adolescents from the NHANES 
study (n = 12,292) found 49.0% prevalence of vitD defi-
ciency in the severely obese group (n = 581) and 34.0% 
in the obese group (n = 1897). In this context, we charac-
terized vitD status in 471 children and adolescents (2–
18 years of age) and analyzed its correlation with gender, 
pubertal period, age, and BMI. An inverse lineal effect of 
BMI and age on 25(OH)-D concentrations was ob-
served in children. Of note, a non-lineal regression mod-
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el showed that 39.6% of 25(OH)-D levels variability was 
explained by BMI [1].
Most of the studies included in meta-analyses had 
cross-sectional designs, which make it more difficult to 
examine the relationship of causality between obesity and 
vitD deficiency. Therefore, longitudinal approaches are of 
great interest. Yet, prospective studies examining the as-
sociation between serum 25(OH)-D and subsequent 
body  weight change have shown inconsistent results [7–
9]. However, the results from a bidirectional Mendelian 
 randomization study, based on 42,024 participants of 
 European descent, suggested a causal relation for a higher 
BMI on reduced serum 25(OH)-D status, while a general 
effect of serum 25(OH)-D on BMI was likely to be absent 
or minimal [10]. A recent meta-analysis based on 10,898 
individuals from the Danish Inter99, the 1958 British 
Birth Cohort, and the Northern Finland Birth Cohort 
1966 found no evidence of an association between 25(OH)-
D and changes in weight or waist circumference, suggest-
ing that associations between 25(OH)-D and changes in 
measures of adiposity were absent or marginal [11].
Several randomized clinical trials have investigated the 
efficacy of vitD supplementation on weight, body compo-
sition, and other metabolic parameters (fat mass, blood 
pressure, lipids, glucose tolerance, and insulin resistance); 
however, their results are contradictory. Some positive 
effects of vitD supplementation on fat mass, triglycerides, 
high density lipoprotein cholesterol, and oral glucose tol-
erance, but adverse effects on low-density lipoprotein 
cholesterol and blood pressure have been described. 
However, because of the reduced number of studies and 
significant heterogeneity in the methodologies applied, 
the current evidence is insufficient to draw conclusions 
[12]. In a recent systematic review, the effect of vitD sup-
plementation (with or without calcium) on inflammatory 
markers, glucose, and insulin sensitivity measures in 
overweight and obese adults was assessed in randomized 
controlled trials [13]. Overall, the results did not find a 
clearly established benefit of vitD supplementation on in-
flammatory and glycemic markers among overweight 
and obese adults. Most of the reported trial outcomes 
were nonsignificant and included considerable bias.
A recently published interesting meta-analysis ad-
dressed the association between vitD3 and the percentage 
of fat mass, pooling together observational studies and 
randomized clinical trials [14]. The results state that the 
25(OH)-D level is inversely correlated with the percent-
age of fat mass, but the meta-analysis did not support the 
hypothesis that vitD supplementation augments body-fat 
loss.
Genetic Factors Linking VitD Status to  
Obesity Pathology
Genetic Mechanisms Influencing VitD Status
It is clear that genetic factors play an important role in 
determining serum 25(OH)-D concentrations. Several 
twin and family studies have reported the vitD heritabil-
ity to be between 23 and 80% [15, 16]. Furthermore, ge-
nome-wide association studies and candidate gene ap-
proaches have reached a consensus in identifying repro-
ducible associations and a replicated genetic architecture 
of vitD [17, 18].
Most of the reported associations involve genes related 
to the vitD metabolism, highlighting important control 
points in vitD molecular pathways. According to the lat-
est conducted genome-wide association studies and can-
didate gene studies [19–22], some of the most remarkable 
associations include genes such as Hydroxyvitamin D-1-α 
hydroxylase (CYP27B1), vitD 25-hydroxylase (CYP2R1), 
vitD binding protein (DBP/GC), vitD receptor (VDR), 
vitD 24-hydroxylase (CYP24A1), 7-dehydrocholesterol 
reductase (DHCR7), retinoid X receptors (RXR), calci-
um-sensing receptor (CASR), NPY, FOXA2, SSTR4, and 
IVL. Several review articles illustrating and detailing all 
these findings have been published by Jolliffe et al. [18] 
and by Bahrami et al. [17]. Specifically, we recommend 
that Jolliffe’s work, which presents a meticulous and de-
tailed table of all the reported associations, be looked into. 
Generally, all associated genes can be categorized into (1) 
genes involved in the upstream production of 25(OH)-D; 
(2) genes involved in the downstream activation of vitD 
to the active ligand 25(OH)-D; (3) carrier proteins (which 
bind to the vitD molecule and the active ligand 25(OH)-
D; (4) receptors and related co-activating proteins (affect-
ing executive ability of the ligand-receptor); and (5) other 
second-order processes that affect the regulatory path-
ways such as calcium concentrations. On the other hand, 
few null/negative associations have also been reported 
[23, 24].
According to these data, though clinical usage is not 
yet applicable, it seems certain that circulating 25(OH)-D 
concentrations is, at least, partially determined by genet-
ic factors.
VitD-Related Genetic Markers and Obesity
Despite the huge evidence of aberrations in the vitD-
endocrine system of people with obesity, the direction of 
the association between vitD and the obese phenotype re-
mains poorly understood. This fact has motivated the sci-
entific community to conduct genetic analyses in order to 
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test whether vitD-related genes, besides serum 25(OH)-D 
concentrations, are also associated with obesity traits. 
The advantage of studying the genetic determinants of 
25(OH)-D levels and obesity is that genetic factors pre-
cede obesity and do not change with obesity status, pro-
viding the opportunity to determine which proteins link 
these 2 conditions at the molecular level, as well as facili-
tating the identification of population subgroups with 
high risk of vitD deficiency.
While mutations in DBP/GC, CYP2R1, and DHCR7 
have been the most widely investigated source of varia-
tion in circulating concentrations of 25(OH)-D [17, 18], 
when we refer to obesity, variation in the VDR gene rep-
resents the bulk of the findings. The fact that limited over-
lap between genetic determinants of vitD status and ge-
netic determinants is associated with obesity is surprising 
and may suggest 2 different things. On the one hand, it 
might suggest a lack of studies investigating the influence 
of variation in genes other than VDR on obesity. On the 
other hand, it might have a biological significance, sug-
gesting that variation in VDR is a more important deter-
minant of obesity phenotype than circulating 25(OH)-D 
concentrations. This last hypothesis makes even more 
sense, since the VDR protein is present in adipose tissue 
(AT) and may contribute to the action of vitD and its 
analogs in adipocytes. In this way, obesity reported that 
associations with VDR polymorphisms could be related 
to either a direct effect of vitD in adipocyte differentiation 
and metabolism, or an indirect effect by modulation of 
insulin secretion.
VDR Genetic Variants
The VDR gene spans 63.49 kb on the 12q12-q14 in the 
human genome. VDR has a considerable noncoding re-
gion including exons 1F–1C and an additional region of 
8 exons (2–9) that codify the VDR protein [25]. The mi-
nor allele of the VDR SNP rs10735810 (also known as 
FokI polymorphism) leads to a VDR protein that is 3 ami-
no acids longer by directly introducing a new translation 
start codon. It influences the activity of VDR protein, 
leads to a fewer transcriptional activator effectiveness, 
and alters the functional properties of the receptor [17].
Mainly 4 VDR polymorphisms, including the rs10735810 
FoKI SNP and 3 additional ones (the rs7975232 ApaI, the 
rs1544410 BsmI, and the rs731236 TaqI), have been ana-
lyzed in relation to genetic predisposition to obesity; how-
ever, findings are contradictory.
Among the studies with statistically significant re-
sults, we highlight a few conducted in a variety of hu-
man ethnicities, including Caucasian, American, and 
Asian populations. The first study to report an associa-
tion between VDR polymorphisms and obesity was con-
ducted by Ye et al. [26]; they found that the VDR TaqI_T 
allele was associated with obesity in French Caucasian 
individuals with early onset of type 2 diabetes. Since 
then, many studies have reported both similar and con-
tradictory results. Bienertová-Vašků et al. [27] conduct-
ed a VDR-genetic analysis in a central-European popu-
lation and found that genetic variability in the VDR re-
gion (including FokI, ApaI, and EcoRV polymorphisms) 
may be an important factor influencing anthropometric 
characteristics associated with obesity. In concordance 
with these results, the VDR TaqI_T allele was associated 
with a higher risk of obesity in Greek individuals (con-
tributing to an elevated BMI of 3 kg/m2 per risk allele) 
in comparison to the alternative G allele [28]. Regard-
ing American populations, in a recent study conduct-
ed on 1,773 healthy women aged 35–80 from Western 
New York State (USA), the VDR rs3782905 polymor-
phism was positively associated with adiposity markers 
[29]. In relation to children, allelic variation in VDR was 
found to be associated with obesity in a population of 
children and adolescents from Brazil [30]. Contrarily, a 
study conducted in a Saudi cohort identified that the 
VDR TaqI_G and Bsm-I_T minor allele polymorphisms 
were significantly more frequent in obese individuals 
[31]. Similar results were found in another study con-
ducted by the same research group, again in Saudi pop-
ulation [32].
The TaqI, BsmI, FokI, ApaI, and other VDR polymor-
phisms have also been associated with obesity-related 
phenotypes in 6 additional studies conducted on Asian 
and European populations [33–38]. All reported associa-
tions for VDR SNPs are summarized in Table 1 and Ta-
ble 2. Although the pathophysiological mechanisms un-
derlying these associations remain unexplained, they 
could be related either to a direct effect of vitD on adipo-
cyte differentiation and metabolism or to an indirect ef-
fect by modulation of insulin secretion. On the other 
hand, null associations between VDR SNPs and obesity 
have also been reported [39–44].
Other VitD-Related Genes (DHCR7, CYP2R1, 
DBP|GC, CYP27B1, CYP27A1, CYP24A1,  
and RXRG)
Studies have also reported associations between vitD-
pathway genes other than VDR (such as DHCR7,  CYP2R1, 
DBP/GC, CYP27B1, CYP27A1, CYP24A1, and RXRG) 
and many obesity-related traits. However, again, the find-
ings have been inconsistent.
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Most positive associations have been identified between 
obesity and the DBP/GC gene in individuals of European 
ancestry [45–47]. Instead, genes such as hydroxylases or 
DHCR7 concentrate the majority of null association results 
[41, 42]. Of note is also the study of Vimaleswaran et al. 
[41], who looked for associations between 100 tagging 
polymorphisms from 8 genes (DHCR7, CYP2R1, DBP/GC, 
CYP27B1, CYP27A1, CYP24A1, VDR, and RXRG) and 
obesity traits in 5,224 participants of European ancestry. 
Their findings, despite the very large sample, suggested 
that the vitD pathway genes are unlikely to have a major 
role in obesity-related traits. Similar results were obtained 
from another study conducted in 6,922 Chinese women, 
where the association between 198 SNPs from CYP27A1, 
CYP27B1, CYP24A1, DBP/GC, and VDR genes and obe-
sity has been investigated [42]. Although in comparison 
with the studies conducted on the VDR gene these studies 
have stronger and more powerful population samples, 
these are rather scarce and further analyses are required in 
order to make firm assertions. Therefore, the listed studies 
point to the fact that the DBP/GC gene could be an impor-
tant protein linking obesity and vitD status, while the rest 
of vitD metabolism genes do not seem to play an important 
role in the etiology of this disease.
As a general conclusion, although genetic markers 
have been reported to be important factors for the devel-
opment of vitD deficiency and its associated phenotypes, 
we can see how vitD-pathway genes remain poorly un-
derstood in the context of obesity and seem to be unes-
sential factors for the development of the disease. Using 
a bidirectional genetic approach, the study concluded 
that a higher BMI (and the genes that predispose to obe-
sity) decreases serum 25(OH)-D levels, whereas lower 
25(OH)-D levels or the genes that are associated with re-
duced serum concentration of 25(OH)-D have, at most, 
very small effects on obesity.
Molecular Mechanism of VitD Related to Obesity
The AT is the main storage organ for vitD and its re-
lease, and it also expresses VDR and enzymes involved in 
vitD metabolism. Indeed, adipocytes respond to 1,25-di-
hydroxyvitamin D (1,25[OH]2D) exposure, and the de-
pots of vitD in AT are proportionate to its plasma con-
centration and release it at a much lower rate that is pro-
portionate to its concentration in AT. VitD, 1,25(OH)2D, 
is active in adipocytes and interacts with membrane re-
ceptors, adaptor molecules, phosphatases, and nuclear 
co-regulator proteins, participating in the control of gene 
expression and cell signaling [48].
VitD and Adipogenesis
The effects of 1,25(OH)2-D are still unclear in the 
adipogenesis process. Adipogenesis is the process of cell 
differentiation by which preadipocytes become mature 
Table 1. Summary of positive associations between VDR polymorphism and obesity-related traits




Reported effect for minor allele or variant
rs10735810 FoKI C (T) Increased sum of skinfold thickness and total % of body fat in central-European population [27]. 
Increased fat free mass in a cohort of older Caucasian men [38].
rs7975232 ApaI A (C) Associated with reduced waist circumference fat in central-European population [27]. Lower risk 
of obesity and overweight in postmenopausal Vietnamese women [33].
rs731236 TaqI A (G) Associated with lower risk of obesity in French Caucasian individuals with early onset of T2D [26].
Significantly more frequent in Saudi obese individuals [31, 32]. Lower risk of obesity in Greek 
individuals [28]. Lower risk of obesity and overweight in postmenopausal Vietnamese women [33].
rs1544410 BsmI C (T) Significantly more frequent in Saudi obese individuals [31, 32]. Positive correlations with height 
and with lean body mass in Brazilian obese children [30]. Higher BMI in postmenopausal 
Vietnamese women [33]. Lower BMI and waist circumference in European ancestry men [35]. 
Lower fat mass in Swedish women [37].
rs3782905 – G (C) Larger waist circumference in female adults recruited from western New York [29].
rs11568820 CDX2 C (T) Associated with larger BMI in Asian individuals [35].
rs4516035 EcoRV T (C) Associated with reduced sum of skin fold thickness in central-European population [27].
VDR, vitamin D receptor; T2D, type 2 diabetes; BMI, body mass index.
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adipocytes. In human cells, 1,25(OH)2-D stimulates ad-
ipogenesis by the upregulation of gene expression en-
zymes of the lipogenesis process such as fatty acid syn-
thase (FASN), fatty acid binding protein (FABP), and 
peroxisome proliferator activator receptor (PPAR)-γ, 
which is the main transcription factor involved in the 
adipogenic differentiation [49]. However, 1,25(OH)2-D 
inhibits this process in mice 3T3–L1 pre-adipocytes, by 
downregulating the transcription factors C/EBPα, C/
EBPβ, and PPAR-γ, and sequestering the nuclear recep-
tor retinoic X receptor (RXR), a member of the nuclear 
receptor superfamily. On the contrary, 1,25(OH)2-D 
up-regulates FASN and lipoprotein lipase (LPL) in hu-
man subcutaneous preadipocytes [50], a process that 
might be mediated by an increased expression of PPAR-γ 
[49].
Generally, vitD, both 25(OH)-D and 1,25(OH)2-D, are 
capable of promoting adipogenic differentiation into ma-
ture adipocytes due to the presence of 1α-hydroxylase in 
mature adipocytes. Additionally, 1,25(OH)2-D stimulates 
the translocation of the glucose transporter 4 (GLUT4) 
into the membrane, promotes adiponectin secretion [50, 
51] and the expression of typical adipocyte genes, such as 
leptin, and inhibits the expression of uncoupling proteins 
in vitro [52]. Thus, VDR directly inhibits the expression 
of the uncoupling protein-1 (UCP1), the critical protein 
for uncoupling fatty acid oxidation in brown AT (BAT). 
As a matter of fact, this process occurs cell autonomously 
and is independent of the physiologic VDR hormone li-
gand, 1,25(OH)2-D [53]. On the other hand, leptin is ca-
pable of increasing the secretion of fibroblast growth fac-
tor 23, which is a negative regulator of renal 1α-hydroxylase, 
Table 2. Details of referenced studies showing positive associations between VDR polymorphism and obesity-related traits
Reference 
number
Sample size and population origin Study design Study variables
[26] 309 French subjects with T2D and 143 
French controls
Case control Disease status, age at diagnosis, duration, arterial 
hypertension, and lipid profile
[27] 882 Central European Caucasian 
individuals of Czech origin (232 males 
and 650 females)
Cohort (population-based study) Anthropometry
[28] 184 individuals (82 with obesity and 
102 controls), from Northern and 
Central Greece
Case control Anthropometric (waist and hip circumference) and 
biochemical parameters (HDL, LDL, cholesterol, and 
triglycerides)
[29] 1,773 healthy female adults recruited 
from western New York
Cohort (population-based study) Anthropometric measurements (BMI, waist circumference, 
and abdominal height) as well as age, education, total 
energy intake, smoking status, alcohol intake, and 
menopausal status
[30] 319 Brazilian obese children and 
adolescents (7–16 years of age)
Intervention study (20-week 
weight-loss program)
Anthropometric measurements, glucose tolerance test, 
and HOMA index
[31] 402 Saudi obese subjects and 489 
non-obese Saudi controls
Case control Anthropometry, cytokines and plasma LPS concentrations
[32] 570 Saudi individuals (285 subjects 
with metabolic syndrome and 285 controls)
Case control Anthropometry and biochemical analysis
[33] 140 healthy postmenopausal Vietnamese 
women with rural origin
Cohort (population-based study) Anthropometry, ethnicity, educational level, occupation, 
medical and reproductive history, dietary, smoking and 
drinking history, as well as physical activity and dietary 
intake questionnaires
[35] 176 unrelated randomly selected European 
ancestry men aged 25–65 years old
Cohort (population-based study) Anthropometric (waist and hip circumference) and 
biochemical parameters (glucose, insulin, HDL, LDL, 
total cholesterol, and triglycerides)
[37] 175 healthy European Ancestry women 
aged 20–39 years old
Cohort (population-based study) Anthropometric measurements (fat mass, lean mass, body 
weight, and body mass index) and muscle strength 
(quadriceps, hamstring, and grip strength)
[38] 302 older European Caucasian men Cohort (population-based study) Anthropometry, physical activity and dietary intake 
questionnaires
VDR, vitamin D receptor; T2D, type 2 diabetes; BMI, body mass index; LPS, lipopolysaccharide; HDL, high-density lipoprotein; LDL, low-density lipopro-
tein.
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thereby closing a negative feedback loop. However, an in-
hibitory effect of 1,25(OH)2-D on leptin secretion by hu-
man adipocytes has been observed in vitro. Indeed, the 
effect of vitD supplementation on leptin levels in humans 
remains poorly investigated and should be further ad-
dressed [52, 54]. Figure 1 summarizes the main vitD ef-
fects on adipogenesis in human adipocytes.
VitD regulates the adipokine secretion in adipocytes, 
such as adiponectin, leptin, and resistin [55]. Adiponec-
tin is an anti-inflammatory and insulin-sensitizing hor-
mone, which is the major adipokine secreted by adipo-
cytes [56]. VitD is associated with low levels of adiponec-
tin in children with obesity, and vitD supplementation 
ameliorates systemic inflammatory biomarkers, includ-
ing adiponectin, in the subjects with type 2 diabetes [57]. 
However, no effect of 1,25(OH)2-D on adiponectin ex-
pression in human adipocyte culture has been observed 
[58].
VitD and Inflammation
Obesity is strongly associated with low-grade inflam-
mation, and with the production and secretion of proin-
flammatory markers. Consequently, the immune cells 
play an important role in AT and immune homeostasis. 
A decreased vitD status is associated with obesity, and re-
cent in vitro studies have described that 1,25(OH)2D ex-
erts anti-inflammatory action on adipocytes [48, 59]. 
VitD promotes a lower chemokine and cytokine release 
by adipocytes and the chemotaxis of monocytes. In AT 





























Fig. 1. Vitamin D effects on adipogenesis and inflammation. 
AMPK, adenosine monophosphate kinase; FABP4, fatty acid-bind-
ing protein 4; FASN, fatty acid synthase; FGF23, fibroblast growth 
factor 23; GLUT4, glucose transporter 4; GPX, gluthathion peroxi-
dase; IL1β, interleukin 1-beta; IL6, interleukin 6; LPL, lipoprotein 
lipase; MAPK, mitogen-activated protein kinase; MCP1, monocyte 
chemotactic protein 1; NF-κB, nuclear factor kappa-light-chain-
enhancer of activated B cells; PPARγ, peroxisome proliferator-ac-
tivator receptors gamma; RXRα, retinoid X receptor; SIRT1, sirtuin 
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AT (VAT) but not from SAT [48, 55]. In VAT in people 
with obesity, there is a reduced adenosine monophos-
phate-activated protein kinase (AMPK) and it is closely 
associated with AT inflammation. In addition, as AMPK 
enhances sirtuin 1 by increasing NAD/NADH ratio and 
decreases AT macrophage infiltration and inflammation, 
both have been proposed as key regulators to prevent 
obesity and obesity-related metabolic dysfunction. A re-
cent study conducted by Chang et al. [59] described that 
vitD deficiency significantly decreased mRNA levels of 
oxidation-related genes. Moreover, significant decre-
ments of sirtuin 1 and AMPK activity were noted in obese 
rats fed with a vitD-insufficient diet. The observed delete-
rious effects of vitD deficiency on AT expansion, immune 
cell infiltration, and inflammatory status suggest that 
vitD plays a beneficial role in adipocyte metabolic me-
tabolism and obesity progression [59].
Recently, it has been established that vitD modulates 
the expression of miRs in adipocytes in vitro. Three miRs 
(miR-146a, miR-150, and miR-155) have been identified, 
which are positively regulated by the tumor necrosis fac-
tor (TNF)-α in human adipocytes and its expression was 
strongly prevented by 1,25(OH)2-D preincubation. Ad-
ditionally, the 3 miRs were increased following high-fat 
diet in epididymal white AT and reduced mice fed with 
high-fat diet supplemented with vitD. Thus, the involve-
ment of nuclear factor kappa-light-chain-enhancer of ac-
tivated B cells (NF-κB) signaling in the induction of these 
miRs was confirmed both in vitro and in vivo using aP2-
p65 transgenic mice. The ability of vitD to deactivate NF-
κB signaling, via p65 and IκB phosphorylation inhibition 
in murine adipocytes, was observed and could constitute 
a driving molecular mechanism (Fig. 1) [60].
Besides the observed effects, vitD decreases proinflam-
matory cytokines and chemokines in mice after an injec-
tion of lipopolysaccharide and in diet-induced obese 
mice, which caused a metabolic inflammation [61]. In hu-
mans, a negative association was found between serum 
25(OH)-D concentration and plasma interleukin (IL)-6 
and TNF-α levels in normal-weight subjects. Neverthe-
less, vitD had no effect on inflammatory biomarkers in 
serum or AT in subjects with obesity [48, 62].
VitD exerts anti-inflammatory effects mediated by the 
inhibition of the NF-κB and mitogen activated protein 
kinase signaling pathways [60]. Additionally, vitD re-
duced toll-like receptor expression, which is increased in 
both immune cells and AT from people with obesity [63–
65]. This is important, since the toll-like receptor is a 
transmembrane protein that pledges classical signaling 
cascades leading to the activation of NF-κB and cytokine 
production such as TNF-α [66]. In human adipocytes, 
1,25(OH)2-D incubation decreases the levels of inflam-
matory markers such as IL-6, monocyte chemotactic pro-
tein-1, and IL-1β (mRNA and protein level). Moreover, 
this treatment downregulates the expression of the TNF-
α-mediated pro-inflammatory marker. A similar effect 
has been observed in adipocyte-macrophage co-culture 
systems in which 1,25(OH)2-D decreased the proinflam-
matory marker expression under basal and TNF-α-
stimulated conditions. The involvement of VDR and NF-
κB was confirmed in this experimental condition. Finally, 
1,25(OH)2-D treatment also provokes the dephosphory-
lating of p38, which is linked to the transcriptional induc-
tion of several Dusp family members. Consequently, a 
higher glucose uptake and AKT phosphorylation were 
observed leading to the fact that low-grade inflammation 
could be linked to vitD deficiency [67]. Another study has 
evaluated the effects of vitD administrations on markers 
of inflammation and oxidative stress in AT of high-fat 
diet induced obese rats. Thus, vitD treatment led to a sig-
nificant reduction in AT TNF-α concentrations in both 
normal diet and high-fat diet obese rats. Monocyte che-
motactic protein-1 concentration was also reduced in AT, 
and among markers of oxidative stress in AT, superoxide 
dismutase, and gluthathione peroxidase concentrations 
significantly increased in AT of high-fat diet supplement-
ed with vitD (Fig. 1). Hence, vitD improved AT oxidative 
stress and inflammatory parameters in obese rats [68].
In summary, vitD plays an important role in the in-
flammation status in adipocytes and AT due to, princi-
pally, its capability for reducing the phosphorylation and 
translocation of NF-κB p65 into the nucleus, and, conse-
quently, decreasing the proinflammatory and oxidative 
stress markers. Further studies are needed to elucidate the 
underlying mechanisms.
Conclusion and Future Recommendations
Based on the extensive scientific bibliography, a posi-
tive association between different levels of BMI and vitD 
deficiency both in adults and children has been clearly 
demonstrated. However, future prospective studies are 
necessary to evaluate the potential causal relationship be-
tween serum concentrations of vitD and obesity. There is 
less available information concerning vitD supplementa-
tion; it remains unclear whether it benefits the adverse 
metabolic profile in obesity. In order to further elucidate 
the role of vitD supplementation on obesity-related bio-
markers, future randomized controlled trials should fo-
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cus on improving the quality of the study design, particu-
larly of trials assessing vitD, as most of the trials had 2 or 
more trial interventions (i.e., weight loss, resistance or ex-
ercise training interventions, with oral vitD supplemen-
tation). Second, the trials had a relatively small sample 
size and a variable vitD dosage and duration. Longer in-
tervention periods of clinically safe higher doses should 
maybe be considered in future studies.
It seems certain that circulating 25(OH)-D concentra-
tions are, at least, partially determined by genetic factors. 
In addition, the analysis of vitD-related genes in the con-
text of obesity is a very interesting approach. In this sense, 
VDR genetic variants have been associated with obesity in 
some but not all studies. Moreover, unanimity in the find-
ings across studies has not been reported for any particu-
lar population. Overall, the presence of so many studies 
with negative results as well as the presence of contradic-
tory findings for certain VDR SNPs suggest that VDR ge-
netic variants are unlikely to play a major role in obesity-
related phenotypes and require further evidence for its as-
sociation. Finally, it is worth mentioning that since most 
of the presented studies with null results failed to obtain 
significant P-values after correction for multiple testing, it 
might be helpful to perform studies with larger and more 
homogenous populations. Perhaps in this way, studies 
would come to consensus in identifying reproducible as-
sociations and would succeed in supporting the “plausi-
ble” hypothesis of VDR as an important gene in obesity.
Finally, a possible molecular mechanism of the rela-
tionship between obesity and vitD deficiency could be the 
capacity of vitD to regulate the gene expression related to 
the adipogenesis process, inflammation, oxidative stress, 
and metabolism in mature adipocytes as summarized in 
Figure 1. However, further studies are needed to elucidate 
the underlying mechanisms.
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